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license (http://creative(AD), and the clusterin protein is thought to play a mechanistic role. We explored the associations
of clusterin plasma levels with incident dementia, AD, and stroke.
Methods: Plasma clusterin was assessed in 1532 nondemented participants from the Framingham
Study Offspring cohort between 1998 and 2001 (mean age, 69 6 6; 53% women). We related
clusterin levels to risk of incident dementia, AD, and stroke using Cox-proportional hazards models
and examined potential interactions.
Results: A significant interaction of plasma clusterin levels with age was observed. Clusterin was
significantly associated with increased risk of dementia among elderly persons (.80 years; hazard
ratio [HR], 95% confidence interval 5 6.25, 1.64–23.89; P 5 .007) and with decreased risk of
dementia (HR 5 0.53, 0.32–0.88; P 5 .013) and stroke (HR 5 0.78, 0.63–0.97; P 5 .029) among
younger participants.
Discussion: The association between plasma clusterin levels and risk of dementia and stroke may be
modified by age or an age-related factor.
 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Epidemiology; Plasma clusterin; Dementia; Alzheimer’s disease; Stroke; Risk factors1. Introduction
Genetic variation within the clusterin (CLU, also
previously called apolipoprotein J, ApoJ) gene has been
associated with risk of Alzheimer’s disease (AD) in mul-
tiple independent genome-wide association studies of
diverse ethnic groups [1]. In addition, among healthy par-
ticipants in the Baltimore Longitudinal Study of Aging,
carriers of the protective CLU allele showed slower rates
of decline in memory performance relative to carriers of: School of public Health, University of Haifa, Mount
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commons.org/licenses/by-nc-nd/4.0/).the risk allele [2]. However, our knowledge is very limited
regarding the mechanisms through which genetic varia-
tion in the clusterin gene modifies the risk of AD. Some
evidence suggests that the clusterin protective variant is
associated with elevated gene expression and higher
plasma clusterin levels [3–6]. In turn, there is substantial
evidence suggesting neuroprotective roles for clusterin
in AD pathogenesis. For instance, clusterin acts as a
chaperone to alter amyloid beta (ab) aggregation and
toxicity, it has a role in ab clearance as well as in lipid
metabolism in the brain, and it modulates inflammation
and inhibits apoptosis [7–9]. In contrast, clusterin
mRNA and protein levels have been shown to be higher
in AD [5,6,10,11] and mild cognitive impairment
[11,12] in some but not all [4,6,13] studies. Clusterinimer’s Association. This is an open access article under the CC BY-NC-ND
N=3,539
N=3,290
N=1,746
N=1,730
N=1,532N=3,206
Attended exam 7
Had clusterin data
Age >60 years
Free of dementia at baseline
Available for dementia 
analysis
Available for stroke 
analysis
Fig. 1. Flow diagram of study participants.
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severity of the disease [6,10] as well as in persons
showing a more rapid decline [6]. Even in nondemented
individuals, clusterin levels are negatively correlated
with performance on tests of global cognition and atten-
tion/processing speed [12], with greater brain atrophy
[6,12] and with a greater decline in white-matter volume
[12]. These findings have led to the hypothesis
that clusterin is elevated in response to brain pathology
to exert its neuroprotective effect. In contrast, in vitro
studies suggest that clusterin can promote amyloid aggre-
gation and toxicity when the clusterin/ab ratio is low
[14,15]. Furthermore, in a longitudinal study of 241 old
individuals, clusterin levels in the cerebrospinal fluid
(CSF) have been related to a greater entorhinal cortex
atrophy rate, and this relationship was observed only
among CSF ab1-42-positive individuals but not among
CSF ab1-42-negative individuals [16]. We postulate that
one reason for these apparently contradictory findings
may be variation in the role of circulating clusterin with
increasing age, inflammation, and amyloid pathology.
It is not clear whether clusterin levels in plasma can serve
as an early predictor of dementia and AD among cognitively
healthy individuals. The discovery of a well-established
peripheral AD biomarker that is easily accessible and cost
effective is of great importance because AD incidence
increases as the population ages, and the ability to identify
high-risk populations is thought to be crucial for the success
of current and future therapies. We tested the hypothesis that
elevated plasma levels of clusterin are associated with a
higher risk of new-onset dementia and AD in cognitively
healthy participants. We then examined whether age and
sex modify this association. An interaction of clusterin
levels with plasma ab was also tested, as the impact of
clusterin may depend on ab burden [16]. Furthermore,
because clusterin has been shown to play a significant role
in inflammation and immune responses [17], we assessed
whether its relationships with dementia/AD risk differ in
individuals with low compared to high serum C-reactive
protein (CRP) levels. Finally, we have explored the
relationship between clusterin levels and the risk for stroke
in the current analysis, as both stroke and dementia share
common risk factors and etiologies [18]. Moreover, clusterin
also has been shown to alter the risk of cardiovascular and
metabolic diseases [19].2. Methods
2.1. Study sample
The FHS is a longitudinal community-based cohort
study that was initiated in 1948 with the enrollment of
5209 participants aged 28–62 years. In 1971, offspring of
the first generation participants and spouses of these
offspring were enrolled as the Offspring cohort (n 5 5124,
age 5 12–58 years). Since their recruitment, participantsfrom the Offspring cohort have had 9 serial examinations
including standardized interviews, physician examinations,
and laboratory testing [20].
The study design is described in Fig. 1. Clusterin was
measured in blood drawn from Offspring participants at
the 7th offspring examination between 1998 and 2001, and
of 3539 who attended that examination, 3290 had blood
samples available for plasma clusterin assay. We excluded
persons age ,60 years because CLU has been associated
only with late-onset dementia, and persons with prevalent
dementia at the 7th Offspring examination. Therefore,
1730 participants remained, of whom, 1532 also had further
follow-up information on cognitive status for at least 1 year
and thus constitute our study sample. For analyses of stroke
outcome, we did not exclude younger participants, so after
excluding 84 participants with prevalent stroke, 3206 of
the 3290 persons with plasma clusterin data were available
for analysis.2.2. Laboratory measurements of clusterin, ab, and CRP
Whole blood was collected in fasting state using a
21-gage needle. For serum preparation, blood was collected
into red top tubes and was allowed to clot in a vertical
position at room temperature for 30 minutes before
centrifugation. For plasma preparation, blood was collected
to EDTA-treated tubes and gently inverted 5–10 times. All
tubes underwent centrifugation at 3000 rpm/1850 g for
30 minutes at 4C. Serum and plasma were then apportioned
into 0.5-mL aliquots and stored at 280C.
All samples were analyzed for beta-amyloid levels at the
Department of Molecular Pharmacology and Experimental
Therapeutics of the Mayo Clinic, Jacksonville, FL.
Quantification of ab in plasma was performed using
INNO-BIA assays (Innogenetics, Ghent, Belgium), which
is a multiplex microsphere-based Luminex xMAP
technique. Intra-assay coefficients of variations (CVs) for
ab1–40 and ab1–42 were 3.2% and 2.6%, and inter-assay
CVs were 10.5% and 7.6%, respectively. Plasma clusterin
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Biomarker Research (SABRe) project 2 panel 1 using a
Luminex xMAP assay. The Multiplex assay had five protein
targets (Clusterin, Apo-A1, Apo-B100, Lp(a), and CRP) and
used a plasma dilution of 1/10,000. The intra-assay %CV for
the clusterin measurements was 3.95%, and Inter-assay %
CVof 8.4%. The assay had a lower limit of quantitation of
1.5 and upper limit of quantitation (ULOQ) of 2.67 !
10^4, with a seven-point calibration curve. Two quality
control (QC) samples were prepared to include five protein
targets in the panel, one a high concentration (QC1) and
the other a low concentration (QC2). To determine the
plate-to-plate and day-to-day performance of each assay
plate, each 96 well assay plate included (1) the standards
in triplicate, (2) the QC1 and QC2 in quadruplicate,
and (3) 32 individual plasma samples in duplicate. The
acceptable range for each FHS assay plate was determined
to be the mean 1/2 3SD. If the QC1 or QC2 value of any
assay plate was out of the range, the plate was repeated.
High-sensitivity CRP levels were determined in serum by
Dade Behring BN100 nephelometer, and the average
interassay coefficients of variation was 2.2%.
2.3. Ascertainment of dementia and AD
All FHS participants are under ongoing continuous
surveillance for onset of cognitive impairment and clinical
dementia. We have previously outlined our screening and
surveillance methods for the development of dementia.
Dementia was diagnosed according to the criteria of the
Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition [21], and AD was diagnosed based on the
criteria of the National Institute of Neurological and
Communicative Disorders and Stroke and the Alzheimer’s
Disease and Related Disorders Association (NINCDS-
ADRDA) for definite, probable, or possible AD [22].
2.4. Definition of covariates
Hypertension was defined as systolic blood pressure
140 mm Hg, diastolic blood pressure 90 mm Hg, or
use of antihypertensive medications; diabetes mellitus
was defined as fasting glucose 7 mmol/L or use of an
antidiabetic therapy; body mass index was defined as weight
(in kilograms) divided by the square of height (in meters).
Current smoking was defined by having smoked at least
one cigarette per day for the previous year. Total and
high-density lipoprotein (HDL) cholesterol were measured
after an overnight fast. APOE genotype was assessed as
previously described [23] and was defined according to
whether the participant had at least one or more ε4 alleles
(yes vs. no).
2.5. Statistical analyses
Age-adjusted and sex-adjusted linear regression models
were constructed to estimate differences in each clinicalmeasure per standard deviation of plasma clusterin levels.
Cox regression models were used to evaluate the association
of plasma clusterin levels with incident dementia, AD, and
stroke. We tested for interaction of clusterin levels with
age, sex, and with two circulating biomarkers, plasma ab
and serum CRP levels, in determining the risk of each
outcome by including these interaction terms in the Cox
regression models. If a significant interaction was found,
we ran a stratified model. Age was stratified into 10-year
age groups for dementia and AD, and into two groups of
above and below 80 years for stroke. All primary analyses
were first adjusted for age and sex, the dementia and AD
outcomes were examined after additional adjustment for
interim strokes. In model 2, we further adjusted for
hypertension, current smoking, diabetes, body mass index,
and APOE ε4 genotype status. In a secondary analysis, we
tested whether CRP modified the association of plasma
clusterin levels with dementia risk. The association of
clusterin and dementia risk was evaluated among persons
with CRP levels in the bottom two tertiles and in the top
tertile, in each age group. All statistical analyses were
done using SAS, v.9.4 (Cary, NC). A two-sided P value
,.05 was considered statistically significant, with the
exception of interaction assessment in which case P value
,.10 was considered statistically significant, owing to low
power of the test.3. Results
Clinical and demographic characteristics of the study
participants at the time of clusterin measurement are listed
in Table 1; their mean age was 69 6 6 years and 806
(53%) were women, mean plasma clusterin was
53 6 13 mg/mL. The mean duration of follow-up for
dementia and AD was 8 6 3 years. The mean duration of
follow-up was shorter among the older participants
(8 6 3 years for baseline age stratum 60–69 years,
7 6 3 years at ages 70–79 years and 6 6 4 years at ages
80–89 years). During the follow-up period, 76 of 1528
participants developed all-cause dementia (58 AD). The
associations of plasma clusterin levels with the baseline
characteristics are listed in Table 1. Clusterin levels were
significantly higher in women, were inversely associated
with age, and were positively associated with higher total
and HDL cholesterol. Of the 3206 participants available
for the stroke analysis, 107 developed a stroke during the
9 6 2 years of follow-up.
Overall, clusterin levels were not associated with risk of
dementia or AD. Higher plasma clusterin levels were
associated with a decreased risk of stroke after additional
adjustment for vascular risk factors (Table 2). We found
significant interactions of age with clusterin levels in
determining the risk of dementia and AD (P 5 .006
and P 5 .012 for dementia and AD, respectively).
Age-specific analyses revealed opposite directions of the
relations of clusterin levels to risk of dementia and AD: in
Table 1
Baseline characteristics of study sample and association with plasma
clusterin levels (N 5 1532)
Characteristics Value
Difference in plasma
clusterin levels (per
100,000 mg/mL)
b 6 SE P value
Age in y 68.6 6 5.7 21.52 6 0.59 .01
Women 806 (52.6) 49.2 6 6.66 ,.0001
Height, in 65.5 6 3.7 20.55 6 1.40 .69
Waist hip ratio 0.97 6 0.07 47.5 6 49.4 .34
Body mass index in kg/m2,* 27.5 (24.7, 30.9) 219.9 6 19.8 .32
Total cholesterol in mg/dL 199 (37) 0.41 6 0.095 ,.0001
HDL cholesterol in mg/dL* 50 (40, 63) 23.9 6 11.8 .04
Systolic blood pressure,
mmHg
132 6 19 0.13 6 0.18 .45
Prevalent hypertensiony 880 (58) 20.38 6 6.85 .96
Hypertension treatment 660 (43) 24.81 6 6.80 .48
Current smoking 123 (8) 7.03 6 12.3 .57
Prevalent diabetesz 246 (16) 29.98 6 9.16 .28
APOE ε4 genotype 341 (23) 23.71 6 8.01 .64
Prevalent cardiovascular
disease
284 (19) 22.05 6 8.86 .82
Prevalent atrial fibrillation 93 (6) 24.60 6 14.1 .74
Prevalent stroke 41 (3) 2.38 6 20.8 .91
Education
No high-school degree 93 (6) 26.03 6 14.9 .69
High-school degree 501 (33) 214.4 6 8.52 .09
Some college 440 (29) 1.35 6 8.78 .88
College graduate 466 (31) Referent —
HOMA-IR* 2.8 (2.0–4.2) 26.42 6 5.66 .26
NOTE. Values in bold indicate P .05.
NOTE. Values are n (%) or mean 6 SD unless otherwise specified.
NOTE. All models are adjusted for age and sex.
NOTE. Differences in plasma levels are for 1 unit increase or for yes
versus no in characteristics.
*Values are median (interquartile range) and b is for increase in 1 unit log
transformation.
yDefined as either systolic blood pressure140 mmHg or diastolic blood
pressure 90 mm Hg or the use of antihypertensive medication.
zDefined as a recorded random blood glucose level 200 mg/dL
(11.1 mmol/L), a previous diagnosis of diabetes mellitus, or the use of
insulin or a hypoglycemic agent.
Table 2
Hazard ratios (95% confidence interval [CI]) associated with 1 SD increase
in clusterin plasma levels
Outcome
Model 1 Model 2
HR (95% CI) P value HR (95% CI) P value
All-cause
dementia*
1.00 (0.79–1.27) .978 1.00 (0.79–1.29) .943
Alzheimer’s
disease*
1.03 (0.79–1.35) .831 1.04 (0.79–1.37) .796
Stroke 0.82 (0.67–1.02) .075 0.79 (0.64–0.99) .042
NOTE. Values in bold indicate P .05.
NOTE. Model 1: Adjusted for age and sex.
NOTE. Model 2: Adjusted in addition for hypertension, smoking,
prevalent diabetes, body mass index and APOE ε4 genotype status.
*Models are also adjusted for prevalent stroke.
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clusterin levels was associated with a 59% (P 5 .005) and
52% (P 5 .038) lower risk of all-cause dementia and AD,
respectively, after adjustment for other risk factors. In the
70-to-79-year age group, the hazard ratios were close to 1,
and the associations were not statistically significant. In
the oldest age group (ages, 80–89 years), we were not able
to assess this relationship while controlling for vascular
risk factors because the numbers were too low; however,
we found that each SD increase in plasma clusterin levels
was associated with about 6 times the risk of dementia
(P 5 .007) and 5 times the risk of AD (P 5 .011), after
adjusting for age and sex (Table 3).
Age did not significantly modify the association between
clusterin levels and the risk of stroke and the associations
within each of the individual 10-year age groups (60–69
years, 70–79 years) were not statistically significant, likelydue to the small numbers in each subgroup. However, we
did observe that higher clusterin levels were associated
with a lower risk of stroke in participants ,80 years
(HR 5 0.75 [0.60–0.95]; P 5 .017). In those who were
80 years old or more, this association was in the opposite
direction although it was not statistically significant
(HR 5 1.22 [0.48–3.06]; Table 3).
No modifying effect of either sex or ab levels on the risk
of any outcome was observed. Among the 60-to-69-year age
group, CRP levels significantly modified the association of
clusterin and incident dementia (P for interaction 5 .057).
In this subsample, increased clusterin levels were associated
with decreased dementia risk only in those with CRP
levels in the bottom 2 tertiles (below 4.25 mg/l;
HR 5 0.41 [0.25–0.68] vs. 0.99 [0.52–1.89] in those with
CRP 4.25). There was no interaction in the 70-to-79-year
age group, and the numbers among the 80-to-89-year age
group were too small to test for interaction. Mean CRP levels
in the 60-to-69-year, 70-to-79-year, and 80-to-89-year age
groups were 4.5 6 6.6, 5.1 6 8.2 and 5.3 6 7.8 mg/l,
respectively.4. Discussion
In our community-based study, age modified the associa-
tion between plasma clusterin levels and incident dementia
and AD such that higher clusterin levels were protective in
younger persons but were associated with a higher risk in
the older participants. Higher clusterin levels were also
associated with reduced risk of stroke in younger persons.
In accordance with our findings, there were no
associations overall between plasma clusterin levels and
risk of incident AD in an earlier report from the Rotterdam
study [10,24]. In the latter, an additional cross-sectional
analysis was conducted which demonstrated an association
of higher plasma clusterin with prevalent AD and with
greater severity of the disease. Other cross-sectional studies
support these findings [6,11] and further suggest that the
CLU genetic variant only influences plasma clusterin
levels in cognitively intact individuals, whereas levels are
Table 3
Hazard ratios (95% confidence interval [CI]) associated with 1 SD increase in clusterin plasma levels stratified by age
Age Cases/N
Model 1 Model 2
HR (95% CI) P value HR (95% CI) P value
All-cause dementia* 60–69 16/937 0.53 (0.32–0.88) .013 0.41 (0.22–0.76) .005
70–79 52/555 1.05 (0.78–1.42) .730 1.10 (0.82–1.48) .539
80–89 8/40 6.25 (1.64–23.89) .007 55.5 (2.73–1130.87) .009
Alzheimer’s disease* 60–69 12/937 0.59 (0.33–1.07) .080 0.48 (0.24–0.96) .038
70–79 39/555 1.03 (0.73–1.45) .883 1.11 (0.79–1.57) .548
80–89 7/40 5.19 (1.45–18.62) .011 — —
Stroke ,80 102/3156 0.78 (0.63–0.97) .029 0.75 (0.60–0.95) .017
80 5/50 1.73 (0.75–3.96) .197 1.22 (0.48–3.06) .678
NOTE. Values in bold indicate P .05.
NOTE. Model 1: Adjusted for age and sex.
NOTE. Model 2: Adjusted in addition for hypertension, smoking, prevalent diabetes, body mass index, and APOE ε4 genotype status.
*Models are also adjusted for prevalent stroke.
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regardless of the genotype [11]. Together, these findings sug-
gest that plasma clusterin levels are elevated only late in the
development of the disease and do not precede it. Whereas
some data suggest that even among dementia-free individ-
uals, clusterin levels in the plasma may be related to AD en-
dophenotypes such as cognitive performance and MRI
measures of white-matter brain injury, these studies were
in older cohorts who are more likely to have clinically unde-
tected AD pathology [6,12,25]. Keeping this in mind, our
findings of a positive association between clusterin levels
and risk of dementia and AD in individuals .80 years
may be explained as an elevation of clusterin levels in
response to brain injury, which in turn may be associated
with a higher risk of dementia and AD. This hypothesis is
also strengthened by the fact that the mean duration of
follow-up for this age group was shorter; thus, it is more
likely that early pathologic brain changes preceding the clin-
ical diagnosis of dementia might already be present when
plasma clusterin was measured. In line with these findings,
previous literature shows that clusterin may have a proamy-
loidogenic effect when ab protein, the clusterin substrate, is
present at a very high molar excess [14,15]. Indeed,
overexposure of endothelial cells to ab has been shown to
induce morphologic and biochemical alterations which
affect blood-brain barrier permeability [26], and as a result,
an accumulation of amyloid deposition in the brain and
simultaneously, elevated clusterin levels in the periphery
may be apparent [27,28], although other mechanisms may
also be involved. This hypothesis has been recently
reinforced in a cohort study of 241 nondemented elderly,
where elevated CSF clusterin levels have been associated
with a greater entorhinal cortex volume loss only when
CSF ab levels were low (indicating increased intracranial
deposition) [16]. We were unable to estimate this ratio in
the CSF or brain and did not observe a modifying effect of
plasma ab on the relationship of clusterin levels and
dementia risk possibly due to poor correlation of ab plasma
and brain/CSF levels.Evidence also exists supporting our opposing findings
in the 60-to-69-year age category compared to those
.80 years. Studies show that clusterin may have a protective
effect on the brain possibly through its interaction with
soluble ab [29]. The latter, but not monomers or
insoluble amyloid fibrils, may be responsible for synaptic
dysfunction in the brains of AD patients and is considered
the most neurotoxic form [30,31]. The clusterin-ab
complex formation significantly prevents aggregation and
polymerization of soluble ab and protects soluble ab from
proteolytic degradation, hence preventing synaptic
dysfunction [29]. Another protective mechanism of clusterin
is its role as a transporter of ab peptides from the brain to the
circulation across the blood-brain barrier [7,9].
Our findings suggest that CRP levels modify the
association of clusterin and dementia risk, such that a
protective effect of clusterin is present only when CRP
levels are low. Emerging evidence suggests that systemic
and central innate immune systems communicate closely,
and several routes of communication have been demon-
strated [32–34]. It is also increasingly recognized that CRP
is a pathogenic factor in AD progress along with ab
oligomer initiation [31,35,36], and recent evidence
suggests that CRP may regulate ab formation [37]. The
role of clusterin in these complex mechanisms needs to be
further explored.
Our results also show that the link of clusterin to dementia
and AD exists in a similar manner with stroke. Although this
finding may point to other clusterin mechanisms that affect
vascular injury, it is also possible that the same clusterin/
ab mechanisms underlie both neurodegeneration and
vascular pathology. Indeed, amyloid deposition in the
arteriolar wall has been shown to enhance vasoconstriction,
and ab is also cytotoxic to endothelial and smooth-muscle
cells, conferring a predisposition to lobar hemorrhage
in advanced age. Alternatively, vascular injury and
parenchymal inflammation perpetuate the cycle of protein
aggregation and oxidation in the brain, which may in turn
lead to cognitive impairment and dementia [31].
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measured in plasma, evidence suggests that these levels
may reflect those of brain regions which are vulnerable to
AD pathology [25]. Furthermore, the involvement of
clusterin in the transport of ab from the brain to the periphery
[27,28] indicates that its levels in the latter are important to
the assessment of AD risk.
It is important to note that due to small numbers of
incident events our results must be considered hypothesis
generating and need to be replicated in larger studies. Yet,
the fact that previous literature exists demonstrating both
neuroprotective and neurotoxic effects of clusterin
under different conditions, and the similar associations
found in the current study for both dementia and stroke
outcomes may indicate that our findings are real. In
addition, owing to the small number of events, we were
unable to assess the relationship between clusterin plasma
levels and the type or severity of dementia or its progression
and to explore cross-sectional associations. The strengths of
this study are its community-based prospective design, the
large sample of dementia-free participants with clusterin
data who were followed-up and the careful surveillance for
endpoints.
In conclusion, we suggest that plasma clusterin is
associated with incident dementia, AD and stroke; however,
age, or age-related factors, may interact with clusterin
leading to contradictory associations among the young-old
and the oldest-old. If validated in other studies, these
findings may have several implications: plasma clusterin
levels can potentially serve as predictors for dementia,
AD, and stroke in specific pre-defined subpopulations and
may allow for better clinical trial design. Moreover,
identifying modifiers of these associations can substantially
leverage our understanding of the mechanisms underlying
dementia, AD, and stroke.Acknowledgments
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1. Systematic review: We searched PubMed for reports
of the association between clusterin plasma levels
and dementia, Alzheimer’s disease (AD), cognition,
and stroke. Previous work has been done mostly us-
ing animal models, and the association with stroke
has been rarely investigated. Cross-sectional studies
in humans suggest that plasma clusterin levels are
higher in persons with AD, cognitive impairment, or
structural brain changes; however, in a prospective
work, no associations with AD risk have been
observed.
2. Interpretation: We are showing for the first time that
age modifies the relationship of clusterin levels with
incident dementia and AD. In accordance with find-
ings from animal models, this may imply that factors
associated with age, such as amyloid-beta-42 and
low-grade inflammation, interact with clusterin to
affect dementia risk.
3. Future directions: Future research should further
explore the role of clusterin as an AD/stroke risk
biomarker and as an active player in AD pathophys-
iology.
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